Nexien BioPharma
Nexien BioPharma is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Nexien BioPharma.
Nexien BioPharma is a company.
Key people at Nexien BioPharma.
Nexien BioPharma, Inc. (OTCMKTS: NXEN) is a development-stage biopharmaceutical company focused on formulating, developing, and commercializing cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies to treat diseases and medical conditions in the United States.[1][2][3] It targets conditions potentially benefiting from cannabinoids and terpenes through proprietary formulations, currently emphasizing synthetic cannabinoids to navigate U.S. regulatory hurdles, with pre-clinical and clinical activities aligned to FDA protocols.[3] The company serves patients with disorders addressable by cannabinoids, solving unmet needs in areas like pain, neurological conditions, or inflammation via innovative drug delivery, though it reports no revenue and ongoing losses (TTM earnings: -$188k, market cap ~$7k as of mid-2025).[2] Growth remains nascent, with no disclosed commercial products or significant traction amid a microcap OTC status.[1][2]
Nexien BioPharma, previously known as Intiva BioPharma Inc., rebranded in September 2018 to reflect its sharpened focus on cannabinoid pharmaceuticals.[1][2] Founded by Richard S. Greenberg, who serves as CEO, Executive VP, and Chairman, the company is headquartered in Glendale, Colorado.[1][3] Key executives include CFO Evan L. Wasoff and COO Robert I. Goldfarb.[1] The idea emerged amid rising interest in cannabinoids for medical use, prompting a strategic shift to proprietary formulations of cannabinoids and terpenes; early pivotal moves involved adopting FDA-compliant development pathways, including "freedom to operate" analyses and patent pursuits, while opting for synthetic cannabinoids to bypass U.S. cannabis-derived research restrictions.[3]
Nexien rides the cannabinoid therapeutics trend, fueled by evolving U.S. cannabis legalization, FDA interest in cannabinoids (e.g., Epidiolex precedent), and demand for non-opioid pain/inflammation treatments amid the opioid crisis.[3] Timing aligns with 2025's maturing synthetic cannabinoid research, reducing Schedule I barriers and enabling faster FDA paths versus plant extracts.[3] Market forces like biotech M&A, terpene synergy studies, and global trial flexibility (e.g., Israel) favor it, though microcap status limits visibility in a crowded pharma sector dominated by larger players.[1][2] It contributes modestly to the ecosystem by advancing IP in cannabinoid delivery, potentially licensing tech or partnering as regulations liberalize.
Nexien's path hinges on advancing pre-clinical trials and securing partnerships/funding to reach clinical milestones, given zero revenue and thin finances—watch for FDA IND filings or synthetic cannabinoid data readouts.[2][3] Trends like AI-accelerated drug discovery, rescheduling momentum, and non-opioid mandates could propel it, but dilution risks and competition from big pharma loom in its microcap reality.[1][2] Influence may grow via acquisitions if pipeline yields proof-of-concept, evolving from OTC obscurity to a niche cannabinoid innovator—tying back to its core bet on regulated, synthetic therapies unlocking medical potential.
Key people at Nexien BioPharma.
